ARS Pharmaceuticals (SPRY) Cash from Operations (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Cash from Operations of 44946000.0 for Q1 2026, down 3.36% sequentially from 43485000.0 in Q4 2025, and down 10.32% YoY from 50117410.15 in Q1 2025.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Cash from Operations (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Cash from Operations for 7 years, with the latest figure at 44946000.0 in Q1 2026.
- Quarterly Cash from Operations fell 10.32% year-over-year to 44946000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 175070000.0 (down 754.67% YoY) and the FY2025 annual result came in at 170866000.0, down 1361.19% from the prior year.
- Cash from Operations eased to 44946000.0 in Q1 2026 per SPRY's latest filing, from 43485000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 42004000.0 in Q4 2024 and troughed at 47047000.0 in Q3 2025.
- A 5-year average of 17741647.06 and a median of 14467000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 341.33% in 2024, then sank 507.18% in 2025.
- Over 5 years, Cash from Operations stood at 20497000.0 in 2022, then rose by 15.09% to 17405000.0 in 2023, then soared by 341.33% to 42004000.0 in 2024, then plunged by 203.53% to 43485000.0 in 2025, then declined by 3.36% to 44946000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 44946000.0, 43485000.0, and 47047000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | ARS Pharmaceuticals | 561.12 Mn | 417.27 Mn | 20.81 Mn | -60.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.93 Mn |
| Mar 31, 2026 | -44.95 Mn |
| Dec 31, 2025 | -43.49 Mn |
| Sep 30, 2025 | -47.05 Mn |
| Jun 30, 2025 | -39.59 Mn |
| Mar 31, 2025 | -40.74 Mn |
| Dec 31, 2024 | 42.00 Mn |
| Sep 30, 2024 | -14.47 Mn |
| Jun 30, 2024 | -7.28 Mn |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -17.41 Mn |
| Sep 30, 2023 | -12.76 Mn |
| Jun 30, 2023 | -16.67 Mn |
| Mar 31, 2023 | -12.43 Mn |
| Dec 31, 2022 | -20.50 Mn |
| Sep 30, 2022 | -5.68 Mn |
| Jun 30, 2022 | -6.97 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | 27.89 Mn |
| Sep 30, 2021 | -19.12 Mn |